DOI: 10.1111/jhn.13315

ORIGINAL ARTICLE



JHND

Health professional attitudes and perceptions of prehabilitation and nutrition before haematopoietic cell transplantation

Laura J. Miller ^{1,2} 💿	Vanessa Hallid	ay ³ John A. Snowden ^{4,5}	
Guruprasad P. Aithal ²	Julia Lee ⁵	Diana M. Greenfield ⁴	

¹Department of Dietetics and Nutrition, Nottingham University Hospitals NHS Trust, Nottingham, UK

²School of Medicine and Population Health, University of Sheffield, Sheffield, UK

³NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, UK

⁴Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK

⁵British Society of Blood and Marrow Transplantation & Cellular Therapy (BSBMTCT), London, UK

Correspondence

Laura J. Miller, Department of Dietetics and Nutrition, Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Hucknall Rd, Nottingham, NG5 1PB, UK. Email: laura.miller44@nhs.net

Funding information

None

Abstract

Background: Nutritional prehabilitation may improve haematopoietic cell transplantation (HCT) outcomes, although little evidence exists. The present study aimed to understand healthcare professional (HCP) perceptions of prehabilitation and nutritional care pre-HCT in UK centres.

Methods: An anonymous online survey (developed and refined via content experts and piloting) was administered via email to multidisciplinary HCPs in 39 UK adult centres, between July 2021 and June 2022. Data are presented as proportions of responses. Routine provision denotes that care was provided >70% of time.

Results: Seventy-seven percent (n = 66) of HCPs, representing 61.5% (n = 24) of UK adult HCT centres, responded. All HCPs supported prehabilitation, proposing feasible implementation between induction chemotherapy (60.4%; n = 40) and first HCT clinic (83.3%; n = 55). Only 12.5% (n = 3) of centres had a dedicated prehabilitation service. Nutrition (87.9%; n = 58), emotional wellbeing (92.4%; n = 61) and exercise (81.8%; n = 61)n = 54) were considered very important constituents. HCPs within half of the HCT centres (n = 12 centres) reported routine use of nutrition screening pre-HCT with a validated tool; 66.7% of HCPs (n = 36) reported using the malnutrition universal screening tool (MUST). Sixty-two percent (n = 41)of HCPs reported those at risk, received nutritional assessments, predominantly by dietitians (91.6%; n = 22) using the dietetic care process (58.3%; n = 14). Body mass index (BMI) was the most frequently reported body composition measure used by HCPs (70.2%, n = 33). Of 59 respondents, non-dietitians most routinely provided dietary advice pre-HCT (82.4%; n = 28 vs. 68%; n = 17, p = 0.2); including high-energy/protein/ fat and neutropenic diet advice. Prophylactic enteral feeding pre-HCT was rare, indicated by low BMI and significant unintentional weight loss. Just under half (n = 25 of 59, 42.4%) HCPs reported exercise advice was given routinely pre-HCT.

Conclusions: Nutrition and prehabilitation pre-HCT are considered important and deliverable by HCPs, but current provision in UK centres is limited and inconsistent.

KEYWORDS

diet, haematopoietic cell transplantation, malnutrition, nutrition, prehabilitation, rehabilitation

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2024 The Authors. Journal of Human Nutrition and Dietetics published by John Wiley & Sons Ltd on behalf of British Dietetic Association.

1

- Prehabilitation was considered important in the context of haematopoietic stem cell transplantation care by all health care professionals (HCPs), although only 12.5% of centres had a dedicated prehabilitation service.
- There are inequities in nutritional care provision prior to haematopoietic cell transplantation (HCT) between transplantation centres.
- Lack of nutrition screening and systematic approaches to body composition assessments may limit the potential to identify and optimise nutritional and functional health prior to HCT.
- Non-dietitians most frequently provided dietary advice pre-HCT. Dietary advice focused on total energy intake (71.1%, *n* = 32) over protein (46.7%, *n* = 21), fat (44.4%, *n* = 20) and fibre (24.4%, *n* = 11).

INTRODUCTION

IHND

Haematopoietic cell transplantation (HCT) is a procedure used to treat malignant and non-malignant haematological disorders. In 2019, primary indications for HCT in centres reporting to the European Society of Blood and Marrow Transplantation (EBMT) were haematological malignancies (88.7%, n = 38,659), followed by non-malignant haematological conditions (3.9%, n = 1691), solid tumours (3.6%, n = 1576), immunological disorders (3.0%, n = 1292) and 'other' indications (0.8%, n = 363).¹ For those recipients with a cancer diagnosis, most will have received numerous cycles of varying intensity chemotherapy regimens prior to HCT to control disease, which may result in an associated risk of deconditioning events.

The HCT process itself is physically and emotionally demanding, negatively impacting the nutritional,^{2,3} functional⁴ and psychological status⁵ of recipients. Patients are treated with high dose cytotoxic therapy (chemotherapy \pm total body irradiation) with the aim of destroying diseased cells. An infusion of stem cells is then given, which engraft and differentiate into mature functioning cells of the blood and immune system, such that the disease indication enters remission and is potentially cured. The type of HCT depends on whether the infused stem cells are collected from the individual (autologous transplant) or from a donor (allogeneic transplant). Allogeneic transplants are associated with greater complications and longer recovery than autologous transplantation.⁶

Nutritional sequelae such as obesity, malnutrition and sarcopenia impact and predict HCT outcomes. Obesity pre-HCT is increasingly prevalent⁷ negatively predicting 100-day readmission, nonrelapse mortality^{8,9} and Graft-versus-Host Disease (GvHD) rates.⁸ Malnutrition, defined as undernutrition in this context, impacts treatment outcome, length of admissions, infectious complications,⁹ fatigue and quality of life.¹⁰ Additionally, secondary sarcopenia, a loss of skeletal muscle mass associated with cancer related inflammation and nutritional deficiencies,¹¹ is an independent negative prognostic indicator for HCT outcomes.¹² These nutritional sequelae both precede and transcend the HCT process, exacerbated by previous treatments, side-effects and complications of HCT such as nutrition impact symptoms and GvHD. Following HCT, there is also an increased risk of further nutrition related comorbidities such as metabolic syndrome and diabetes,^{6,13} which can develop as a late effect.^{14,15}

Despite the potential impact of nutrition sequelae on HCT outcomes, a survey of European HCT centres¹⁶ showed nutrition practices were inconsistent and failed to meet international guidelines.¹⁷ Alongside this, although international accreditation standards for HCT in the USA and Europe recommend having access to some allied services, they do not stipulate definitive need for dietetic support of patients.¹⁸

Intervening early with proactive nutritional care may help mitigate some of these risks and contribute to improved HCT outcomes. The UK National Health Service (NHS) long-term plan calls for personalised¹⁹ proactive²⁰ interventions that enable self-management.²¹ Prehabilitation is a package of proactive interventions aiming to optimise physical (including nutritional) and emotional wellbeing before treatment, through the identification of deficits and delivery of personalised intervention(s).²² There are numerous population specific definitions for prehabilitation, such as the definition by Silver and Baima²² for cancer: "a process on the cancer continuum of care that occurs between the time of cancer diagnosis and the beginning of acute treatment including assessment of baseline function, identification of impairments, and provision of interventions that promote health in order to reduce the incidence and/or severity of future impairments". These definitions can help to characterise programme aims, context and constituents, informing research, policy and clinical service delivery.

Surgical prehabilitation programmes have been shown to reduce hospital length of stay, infection rates and improve quality of life.²³ This has led to increasing interest in its potential role in haematological settings; however, few studies of prehabilitation in HCT exist.²⁴ Additionally, nutrition interventions within prehabilitation studies have been shown to vary, lack detailed description and are often poorly evaluated.²⁵ Despite the expansion of prehabilitation services to HCT settings, the prehabilitation services currently being delivered in the UK, nutrition practices pre-HCT and the feasibility of nutritional prehabilitation in this context are all poorly understood.

The present study aimed to explore the current provision and healthcare professional (HCP) perceptions of prehabilitation and nutritional care pre-HCT within UK and Republic of Ireland HCT centres. Definitions of prehabilitation in the context of HCT, perceptions on its implementation, and nutrition practices such as screening, assessment and intervention delivery were also investigated.

METHODS

Questionnaire development and piloting

The questionnaire was developed by six content experts covering nutrition and metabolism, prehabilitation and HCT. Questionnaire contents were informed by prehabilitation guidelines,²⁶ nutrition practices in HCT^{3,17} and similar studies in other cohorts.¹⁶ Question and answer constructs were reviewed by experts and rationale for both questions and wording was discussed.²⁷ Amendments were made and the full questionnaire piloted by five HCPs for feedback, which was then incorporated into a definitive version. A range of question types including five-point Likert scale, multiple response and open-ended questions were included. Participants were also presented with the definition of prehabilitation by Silver and Baima²² to consider its relevance for the context of prehabilitation in HCT.

Dissemination and data collection

The survey was imported onto REDCap Cloud, version 1.4 (https://www.redcapcloud.com) and distributed via email by the British Society of Blood and Marrow Transplantation and Cellular Therapy to clinical leads at 39 adult HCT centres between August 2020 and February 2022. The questionnaire was also disseminated via email to dietetic departments within centres. Invitation emails included a summary of the study and the participant information sheet. No data or precedents on sample size were available; therefore, a pragmatic multidisciplinary recruitment target of one nurse, dietitian and doctor from each centre was determined. Three email reminders were sent in September 2020, July 2021 and BDA Triventer

January 2022. Online consent was taken as part of the questionnaire, and all responses were anonymous.

Data analysis

Responses were downloaded from REDCap cloud to Excel 365, version 2312 (Microsoft Corp.). Incomplete and duplicate entries were removed. Quantitative data were imported to SPSS, version 29 (IBM Corp.) for analysis. Proportions of respondents for each item were reported (%, n). When reporting prehabilitation or nutritional practices within a centre the average response for all HCPs within a centre were used. Provider of dietary advice delivered was dichotomised into dietitians and non-dietitians to review differences in advice by HCPs. Because of the small sample, size correlations were not considered. Thematic analysis²⁸ was used for qualitative free text question data, initial analyses were conducted by one of the investigators (LJM) and reviewed by another (DG) with discrepancies reviewed, discussed and agreed.

Ethical statement

The study was registered with the Health Research Authority who confirmed that ethics approval was not required. All local governance and GDPR processes were followed. Clinicaltrials.gov: NCT05352789.

RESULTS

Respondent characteristics

Ninety-nine responses were received, 23 were excluded as a result of no parts of the consent or survey being completed. This left 66 unique respondents, from 24 transplant centres, with responding centres covering Great Britain and Republic of Ireland, and no Northern Irish centres responding. Most respondents were dietitians (39.4%, n = 26) (84.6%, n = 22; haematology specialist dietitians), followed by haematologists (21.2%, n = 14) and nurses (25.8%, n = 17)). Other staff included physiotherapist (6.1%, n = 4), occupational therapist (3%, n = 2), HCT coordinators (3%, n = 2) and one clinical psychologist (1.5%). Most respondents (80.3%, n = 53) reported they delivered clinical care pre-HCT.

Responses were received from HCPs in 24 HCT centres (61.5% of target), 75% (n = 18) of centres represented by the HCP respondents delivered both autologous and allogeneic HCT with an average of 152 (72–240) transplants per year, and 25% (n = 6) delivered autologous only, with an average of 39 (12–70) transplants per year. Respondent and centre characteristics are provided in Table 1.

 TABLE 1
 Respondent characteristics and that of their associated transplant centres.

Healthcare professional (HCP) (<i>N</i> = 66)	N (%)
Profession	
Dietitian ($N = 26; 39.4$)	
Haematology specialist	22 (33.3)
Nonspecialist	4 (6.1)
Nurse (<i>N</i> = 17; 25.7)	
Clinical nurse specialist	14 (21.2)
Nurse (other)	3 (4.5)
Doctor (<i>N</i> = 14; 21.2)	
Haematologist (consultant)	14 (21.2)
Haematology (doctor other)	0
Allied health professional ($N = 7$; 10.6)	
Physiotherapist	4 (6.1)
Occupational therapist	2 (3)
Psychologist	1 (1.5)
Bone marrow transplant coordinator	2 (3)
Proportion delivering clinical care pre-HCT	53 (80.3)
Haematopoietic cell transplant centre ($N = 23$)	N (%)
Treated populations in adult centres	
≥18 years	15 (65.2)
≥16 years	8 (34.8)
Combined adult/paediatric unit	7 (30.4)
Combined adult/teenage and young adults' unit	9 (39.1)
Locality of centres	
Northern England	4 (17.4)
Midlands	4 (17.4)
Eastern England	1 (4.3)
Southern England	5 (21.7)
London	4 (17.4)
Scotland	2 (8.7)
Wales	1 (4.3)
Northern Ireland	0
Republic of Ireland	2 (8.7)
JACIE accredited centres	
Initial accreditation	2 (8.7)
Re-accredited	12(52.2)
Not accredited	9 (39.1)

Abbreviation: JACIE, Joint Accreditation Committee ISCT-Europe & EBMT.

HCT prehabilitation provision

HCPs within only three centres (12.5%) showed agreement on the provision of a dedicated multidisciplinary prehabilitation service for HCT in their centre. In some centres, there was disagreement between HCPs on whether dedicated prehabilitation was provided or not (16.7%, n=4), with 4.2% (n=1) reporting that they were unsure. Potential reported explanations for this included nurse led prehabilitation with option to refer into support services such as dietetics, but no dedicated prehabilitation capacity.

Defining prehabilitation in the context of HCT

When asked to consider the definition of prehabilitation by Silver and Baima²² in the context of HCT, 57.6% (n = 38) of HCPs felt the current definition could be applied to HCT without modification. However, 21.2% (n = 14) felt modifications were required and 18.2% (n = 12) were unsure; 50% (n = 6) of which went on to suggest modifications. Further details of HCP suggested changes are provided in Table 2. Themes derived from these suggestions were then used to inform a HCT-specific refinement of the definition by Silver and Baima.²²

Proposed definition of prehabilitation in HCT by Miller et al.

"Prehabilitation is part of a proactive multiphasic rehabilitation continuum, involving early assessment of baseline function (screening), identification of impairments (assessment), and provision of interventions that promote physical and psychological wellbeing prior to HCT. It is a personalised holistic process that empowers recipients and families via multidisciplinary expert guidance with the aim of reducing the incidence and/or severity of future impairments".

Implementation of prehabilitation in HCT

Timing

All respondents felt prehabilitation should be considered as part of future HCT services. Most (83.3%, n = 55) felt this could be implemented in the pre-HCT assessment clinic; for example, end of consolidation chemotherapy or other treatment. However, 60.6% (n = 40) felt prehabilitation could be delivered either during or at the end of induction chemotherapy before consolidation chemotherapy, with 10.6% (n = 7) suggesting delivery at the point of diagnosis. Figure 1 shows prehabilitation timing perspectives of dietitians' and non-dietitians.

en diagnosis and treatment for acute national patients – would Nurse (1) hab during induction chemo and prior to HCT" often already on active/acute treatment (chemo) so the definition Dietitian (9)							I nere is very nuite time between diagnosis and treatment for acute naematology patients – would		respondents $(v - z_0)$ Selection of exemptiar quotes	respondents ^a ($N = 20$) Selection of exemplar quotes ^b
often already on active/acute treatment (chemo) so the definition	MT are often already on active/acute treatment (chemo) so the definition				be better to undertake prehab during induction chemo and prior to HCI^{m}		be better to undertake prehab during induction chemo and prior to HCT"	10 "There is very little time between diagnosis and treatment for acute haematology patients – would be better to undertake prehab during induction chemo and prior to HCT"	10 "There is very little time between diagnosis and treatment for acute haematology patients – would be better to undertake prehab during induction chemo and prior to HCT"	"There is very little time between diagnosis and treatment for acute haematology patients – would be better to undertake prehab during induction chemo and prior to HCT"
porate this, for example time of decision for a BMT and admission	to incorporate this, for example time of decision for a BMT and admission	ab for BMT are often already on active/acute treatment (chemo) so the definition amended to incorporate this, for example time of decision for a BMT and admission	ent prehab for BMT are often already on active/acute treatment (chemo) so the definition tould be amended to incorporate this, for example time of decision for a BMT and admission τ BMT.	"Patient prehab for BMT are often already on active/acute treatment (chemo) so the definition should be amended to incorporate this, for example time of decision for a BMT and admission for BMT"	"Patient prehab for BMT are often already on active/acute treatment (chemo) so the definition should be amended to incorporate this, for example time of decision for a BMT and admission for BMT"	"Patient prehab for BMT are often already on active/acute treatment (chemo) so the definition should be amended to incorporate this, for example time of decision for a BMT and admission for BMT"	"Patient prehab for BMT are often already on active/acute treatment (chemo) so the definition should be amended to incorporate this, for example time of decision for a BMT and admission for BMT"	"Patient prehab for BMT are often already on active/acute treatment (chemo) so the definition should be amended to incorporate this, for example time of decision for a BMT and admission for BMT"	"Patient prehab for BMT are often already on active/acute treatment (chemo) so the definition should be amended to incorporate this, for example time of decision for a BMT and admission for BMT"	"Patient prehab for BMT are often already on active/acute treatment (chemo) so the definition should be amended to incorporate this, for example time of decision for a BMT and admission for BMT"
may not always be possible to intervene before first line treatme g losses than optimisation"	timent it may not always be possible to intervene before first line treatme nitigating losses than optimisation"	gent treatment it may not always be possible to intervene before first line treatme be able mitigating losses than optimisation"	ase of urgent treatment it may not always be possible to intervene before first line treatme it may be able mitigating losses than optimisation"	"In case of urgent treatment it may not always be possible to intervene before first line treatment Dietitian (16) so it may be able mitigating losses than optimisation"	"In case of urgent treatment it may not always be possible to intervene before first line treatme so it may be able mitigating losses than optimisation"	"In case of urgent treatment it may not always be possible to intervene before first line treatme so it may be able mitigating losses than optimisation"	"In case of urgent treatment it may not always be possible to intervene before first line treatme so it may be able mitigating losses than optimisation"	"In case of urgent treatment it may not always be possible to intervene before first line treatme so it may be able mitigating losses than optimisation"	"In case of urgent treatment it may not always be possible to intervene before first line treatme so it may be able mitigating losses than optimisation"	"In case of urgent treatment it may not always be possible to intervene before first line treatme so it may be able mitigating losses than optimisation"
ses of treatment in cancer treatment over a life course"	ute phases of treatment in cancer treatment over a life course"	ultiple acute phases of treatment in cancer treatment over a life course"	re are multiple acute phases of treatment in cancer treatment over a life course"	"There are multiple acute phases of treatment in cancer treatment over a life course"	"There are multiple acute phases of treatment in cancer treatment over a life course"	"There are multiple acute phases of treatment in cancer treatment over a life course"	"There are multiple acute phases of treatment in cancer treatment over a life course"	9	9	
	inuum"	n a continuum"	ssment on a continuum"	"assessment on a continuum"	"assessment on a continuum"	"assessment on a continuum"	"assessment on a continuum"	"assessment on a continuum"	"assessment on a continuum"	"assessment on a continuum"
the fact that there is no real time between diagnosis and treatment statement then again $Pre\ Tx$.	ion to the fact that there is no real time between diagnosis and treatment s d on treatment then again Pre Tx "	e in relation to the fact that there is no real time between diagnosis and treatment s e assessed on treatment then again Pre Tx^{*}	ds change in relation to the fact that there is no real time between diagnosis and treatment seds to be assessed on treatment then again $Pre\ Tx$ "	"Needs change in relation to the fact that there is no real time between diagnosis and treatment so needs to be assessed on treatment then again $Pre Tx$ "	"Needs change in relation to the fact that there is no real time between diagnosis and treatment s needs to be assessed on treatment then again Pre Tx"	"Needs change in relation to the fact that there is no real time between diagnosis and treatment s needs to be assessed on treatment then again Pre Tx"	"Needs change in relation to the fact that there is no real time between diagnosis and treatment s needs to be assessed on treatment then again Pre Tx"	"Needs change in relation to the fact that there is no real time between diagnosis and treatment s needs to be assessed on treatment then again Pre Tx"	"Needs change in relation to the fact that there is no real time between diagnosis and treatment s needs to be assessed on treatment then again Pre Tx"	"Needs change in relation to the fact that there is no real time between diagnosis and treatment s needs to be assessed on treatment then again Pre Tx"
different depending on previous acute treatment"	a can be different depending on previous acute treatment"	ervention can be different depending on previous acute treatment"	ng of intervention can be different depending on previous acute treatment"	"timing of intervention can be different depending on previous acute treatment"	"timing of intervention can be different depending on previous acute treatment"	"timing of intervention can be different depending on previous acute treatment"	"timing of intervention can be different depending on previous acute treatment"	"timing of intervention can be different depending on previous acute treatment"	"timing of intervention can be different depending on previous acute treatment"	"timing of intervention can be different depending on previous acute treatment"
ant in non-malignant conditions, that is MS, sickle cell disease,	r transplant in non-malignant conditions, that is MS, sickle cell disease,	count for transplant in non-malignant conditions, that is MS, sickle cell disease, acmia"	s not account for transplant in non-malignant conditions, that is MS, sickle cell disease, plastic anaemia"	"Does not account for transplant in non-malignant conditions, that is MS, sickle cell disease, aplastic anaemia"	"Does not account for transplant in non-malignant conditions, that is MS, sickle cell disease, aplastic anaemia"	"Does not account for transplant in non-malignant conditions, that is MS, sickle cell disease, aplastic anaemia"	"Does not account for transplant in non-malignant conditions, that is MS, sickle cell disease, aplastic anaemia"		ĸ	
ave a cancer diagnosis"	do not have a cancer diagnosis"	patients do not have a cancer diagnosis"	e HCT patients do not have a cancer diagnosis"	"Some HCT patients do not have a cancer diagnosis"	"Some HCT patients do not have a cancer diagnosis"	"Some HCT patients do not have a cancer diagnosis"	"Some HCT patients do not have a cancer diagnosis"	"Some HCT patients do not have a cancer diagnosis"	"Some HCT patients do not have a cancer diagnosis"	"Some HCT patients do not have a cancer diagnosis"
ut it does not support the idea of utilising in patient selecti	nition, but it does not support the idea of utilising in patient selecti	ood definition, but it does not support the idea of utilising in patient selecti	a very good definition, but it does not support the idea of utilising in patient selectiansplant"	"It is a very good definition, but it does not support the idea of utilising in patient selection for transplant"				2 "It	2 "It	IJ"
at the time of diagnosis"	or HCT at the time of diagnosis"	a plan for HCT at the time of diagnosis"	/ not be a plan for HCT at the time of diagnosis"	"May not be a plan for HCT at the time of diagnosis"	"May not be a plan for HCT at the time of diagnosis"	"May not be a plan for HCT at the time of diagnosis"	"May not be a plan for HCT at the time of diagnosis"	"May not be a plan for HCT at the time of diagnosis"	"May not be a plan for HCT at the time of diagnosis"	"May not be a plan for HCT at the time of diagnosis"
at the time of diagnosis" he whole MDT to provide prehabilitation, an opportunity	or HCT at the time of diagnosis" job of the whole MDT to provide prehabilitation, an opportunity	a plan for HCT at the time of diagnosis" it is the job of the whole MDT to provide prehabilitation, an opportunity	/ not be a plan for HCT at the time of diagnosis" in how it is the job of the whole MDT to provide prehabilitation, an opportunity	"May not be a plan for HCT at the time of diagnosis" "Add in how it is the job of the whole MDT to provide prehabilitation, an opportunity for economics to contribute"	"May not be a plan for HCT at the time of diagnosis" "Add in how it is the job of the whole MDT to provide prehabilitation, an opportunity	"May not be a plan for HCT at the time of diagnosis" "Add in how it is the job of the whole MDT to provide prehabilitation, an opportunity	"May not be a plan for HCT at the time of diagnosis" "Add in how it is the job of the whole MDT to provide prehabilitation, an opportunity			"May not be a plan for HCT at the time of diagnosis"
at the time of diagnosis" he whole MDT to provide prehabilitation, an oppor	or HCT at the time of diagnosis" job of the whole MDT to provide prehabilitation, an oppor	a plan for HCT at the time of diagnosis" it is the job of the whole MDT to provide prehabilitation, an oppor	/ not be a plan for HCT at the time of diagnosis" in how it is the job of the whole MDT to provide prehabilitation, an opportion is contributed.	"May not be a plan for HCT at the time of diagnosis" "Add in how it is the job of the whole MDT to provide prehabilitation, an oppor	"May not be a plan for HCT at the time of diagnosis" "Add in how it is the job of the whole MDT to provide prehabilitation, an oppor	"May not be a plan for HCT at the time of diagnosis" "Add in how it is the job of the whole MDT to provide prehabilitation, an oppor				"May not be a plan for HCT at the time of diagnosis"
different depending on previous acute trea ant in non-malignant conditions, that is M ave a cancer diagnosis" ut it does not support the idea of utilising at the time of diagnosis" the time of diagnosis"	a can be different depending on previous acute trea transplant in non-malignant conditions, that is M do not have a cancer diagnosis" nition, but it does not support the idea of utilising or HCT at the time of diagnosis"	ervention can be different depending on previous acute trea count for transplant in non-malignant conditions, that is M atemia" oad definition, but it does not support the idea of utilising a plan for HCT at the time of diagnosis" it is the job of the whole MDT to provide prehabilitation,	ng of intervention can be different depending on previous acute trea s not account for transplant in non-malignant conditions, that is M plastic anaemia" the HCT patients do not have a cancer diagnosis" a very good definition, but it does not support the idea of utilising ansplant" / not be a plan for HCT at the time of diagnosis" in how it is the job of the whole MDT to provide prehabilitation,	 "timing of intervention can be different depending on previous acute trea "Does not account for transplant in non-malignant conditions, that is M aplastic anaemia" "Some HCT patients do not have a cancer diagnosis" "Some HCT patients do not have a cancer diagnosis" "Some HCT patients do not have a cancer diagnosis" "May not be a plan for HCT at the time of diagnosis" "Add in how it is the job of the whole MDT to provide prehabilitation, encoded to the second terms of the whole MDT to provide prehabilitation, " 	 "timing of intervention can be different depending on previous acute trea "Does not account for transplant in non-malignant conditions, that is M aplastic anaemia" "Some HCT patients do not have a cancer diagnosis" "Some HCT patients do not have a cancer diagnosis" "It is a very good definition, but it does not support the idea of utilising transplant" "May not be a plan for HCT at the time of diagnosis" "Add in how it is the job of the whole MDT to provide prehabilitation. 	 "timing of intervention can be different depending on previous acute trea "Does not account for transplant in non-malignant conditions, that is M aplastic anaemia" "Some HCT patients do not have a cancer diagnosis" "It is a very good definition, but it does not support the idea of utilising transplant" "May not be a plan for HCT at the time of diagnosis" "Add in how it is the job of the whole MDT to provide prehabilitation, 	.ii , , , , , , , , , , , , , , , , , ,	т, т, т, т, т, т, т, т, т, т, т, т, т,	"ti 3 "D "S tion 2 "It	"ui" 3 * D *S *1t tion 2 * M
g losses than optimisation" ses of treatment in cancer treatm the fact that there is no real time be atment then again Pre Tx" different depending on previous ant in non-malignant conditions, ant in non-malignant conditions, at it does not support the idea o at the time of diagnosis" the whole MDT to provide prehal	nitigating losses than optimisation" ute phases of treatment in cancer treatm inuum" ion to the fact that there is no real time b d on treatment then again Pre Tx" a can be different depending on previous ransplant in non-malignant conditions, fo not have a cancer diagnosis" do not have a cancer diagnosis" nition, but it does not support the idea o nition, but it does not support the idea o iob of the whole MDT to provide prehal	be able mitigating losses than optimisation" altiple acute phases of treatment in cancer treatm n a continuum" e in relation to the fact that there is no real time b e assessed on treatment then again Pre Tx" ervention can be different depending on previous ervention can be different depending on previous ount for transplant in non-malignant conditions, aemia" ood definition, but it does not support the idea o a plan for HCT at the time of diagnosis" a plan for HCT at the time of diagnosis"	o it may be able mitigating losses than optimisation" re are multiple acute phases of treatment in cancer treatm ssment on a continuum" ds change in relation to the fact that there is no real time b eeds to be assessed on treatment then again Pre Tx" ng of intervention can be different depending on previous s not account for transplant in non-malignant conditions, plastic anaemia" the HCT patients do not have a cancer diagnosis" e HCT patients do not have a cancer diagnosis" a very good definition, but it does not support the idea o ansplant" / not be a plan for HCT at the time of diagnosis" in how it is the job of the whole MDT to provide prehal	 so it may be able mitigating losses than optimisation" "There are multiple acute phases of treatment in cancer treatm "assessment on a continuum" "Needs change in relation to the fact that there is no real time be needs to be assessed on treatment then again Pre Tx" "Itiming of intervention can be different depending on previous "Does not account for transplant in non-malignant conditions, aplastic anaemia" "Some HCT patients do not have a cancer diagnosis" "It is a very good definition, but it does not support the idea of transplant" "May not be a plan for HCT at the time of diagnosis" "Add in how it is the job of the whole MDT to provide prehal condition to condition to the substitute to contribute" 	 so it may be able mitigating losses than optimisation" "There are multiple acute phases of treatment in cancer treatm "assessment on a continuum" "Needs change in relation to the fact that there is no real time b needs to be assessed on treatment then again Pre Tx" "Iming of intervention can be different depending on previous "timing of intervention can be different depending on previous aplastic anaemia" "Some HCT patients do not have a cancer diagnosis" "It is a very good definition, but it does not support the idea of transplant" "May not be a plan for HCT at the time of diagnosis" 	 so it may be able mitigating losses than optimisation" "There are multiple acute phases of treatment in cancer treatm "assessment on a continuum" "Needs change in relation to the fact that there is no real time be needs to be assessed on treatment then again Pre Tx" "Iming of intervention can be different depending on previous "Does not account for transplant in non-malignant conditions, aplastic anaemia" "Some HCT patients do not have a cancer diagnosis" "It is a very good definition, but it does not support the idea c transplant" "May not be a plan for HCT at the time of diagnosis" "Add in how it is the job of the whole MDT to provide prehal 		atment 6 3 2	ic treatment 6 3 tion 2	ic treatment 6 3 tion 2
may not always be poss g losses than optimisati, ses of treatment in canco e fact that there is no re atment then again Pre 7 different depending on ant in non-malignant cc ave a cancer diagnosis" ut it does not support t at the time of diagnosis ne whole MDT to provi	timent it may not always be poss nitigating losses than optimisati cute phases of treatment in cance innum" ion to the fact that there is no re d on treatment then again Pre 7 a can be different depending on a can be different depending on transplant in non-malignant cc do not have a cancer diagnosis" nition, but it does not support t nition, but it does not support t	gent treatment it may not always be poss be able mitigating losses than optimisati, altiple acute phases of treatment in canc n a continuum" e in relation to the fact that there is no re e assessed on treatment then again Pre 7 e assessed on treatment then again Pre 7 e revention can be different depending on ervention can be different depending on count for transplant in non-malignant cc aemia" out for transplant in non-malignant cc aemia" attents do not have a cancer diagnosis" ood definition, but it does not support t a plan for HCT at the time of diagnosis it is the job of the whole MDT to provi	ase of urgent treatment it may not always be poss of it may be able mitigating losses than optimisation the are multiple acute phases of treatment in canco- ssment on a continuum" ds change in relation to the fact that there is no re- eds to be assessed on treatment then again Pre 7 ng of intervention can be different depending on s not account for transplant in non-malignant co plastic anaemia" the HCT patients do not have a cancer diagnosis" a very good definition, but it does not support t ansplant" in how it is the job of the whole MDT to provi- cientes to contribute"	 "In case of urgent treatment it may not always be poss so it may be able mitigating losses than optimisatio "There are multiple acute phases of treatment in canc "assessment on a continuum" "Needs change in relation to the fact that there is no re "assessment on be assessed on treatment then again Pre 7 "timing of intervention can be different depending on "Does not account for transplant in non-malignant cc aplastic anaemia" "Some HCT patients do not have a cancer diagnosis" "It is a very good definition, but it does not support t transplant" "May not be a plan for HCT at the time of diagnosis "Add in how it is the job of the whole MDT to provi 	"In case of urgent treatment it may not always be poss so it may be able mitigating losses than optimisati, "There are multiple acute phases of treatment in cano "assessment on a continuum" "Needs change in relation to the fact that there is no re needs to be assessed on treatment then again Pre 7 "timing of intervention can be different depending on "Does not account for transplant in non-malignant cc aplastic anaemia" "Some HCT patients do not have a cancer diagnosis" "It is a very good definition, but it does not support t transplant" "May not be a plan for HCT at the time of diagnosis "Add in how it is the job of the whole MDT to provi	 "In case of urgent treatment it may not always be poss so it may be able mitigating losses than optimisati. "There are multiple acute phases of treatment in cano "assessment on a continuum" "Needs change in relation to the fact that there is no re needs to be assessed on treatment then again Pre 7 "timing of intervention can be different depending on "timing of intervention can be different depending on aplastic anaemia" "Some HCT patients do not have a cancer diagnosis" "It is a very good definition, but it does not support t transplant" "May not be a plan for HCT at the time of diagnosis" 		atment 6 3 2	ic treatment 6 3 tion 2	ic treatment 6 3 tion 2
may not alway g losses than o ses of treatmen the fact that ther atment then ag different depen ant in non-mal ave a cancer di ave a cancer di ave ti does not i at the time of c	timent it may not alway nitigating losses than o cute phases of treatmen inuum" ion to the fact that ther ad on treatment then ag a can be different depei transplant in non-mal do not have a cancer di nition, but it does not t nition, but it does not t	gent treatment it may not alway be able mitigating losses than o. Iltiple acute phases of treatmen a continuum" e in relation to the fact that ther e assessed on treatment then ag ervention can be different depel ervention can be different depel action for transplant in non-mal action for transplant in non-mal action of the vhole not to ood definition, but it does not to a plan for HCT at the time of o	ase of urgent treatment it may not alway it may be able mitigating losses than o re are multiple acute phases of treatmen ssment on a continuum" ds change in relation to the fact that ther eds to be assessed on treatment then ag ng of intervention can be different deper s not account for transplant in non-mal blastic anaemia" the HCT patients do not have a cancer di a very good definition, but it does not ansplant" in how it is the job of the whole MDT in how it is the job of the whole MDT	 "In case of urgent treatment it may not alway so it may be able mitigating losses than o "There are multiple acute phases of treatmen "assessment on a continuum" "Needs change in relation to the fact that ther needs to be assessed on treatment then ag "timing of intervention can be different deper "Does not account for transplant in non-mal aplastic anaemia" "Some HCT patients do not have a cancer di "It is a very good definition, but it does not transplant" "May not be a plan for HCT at the time of cancerdii is the job of the whole MDT cancerdinate to constribute" 	"In case of urgent treatment it may not alway so it may be able mitigating losses than o "There are multiple acute phases of treatmen "assessment on a continuum" "Needs change in relation to the fact that ther needs to be assessed on treatment then ag "timing of intervention can be different deper "Does not account for transplant in non-mal aplastic anaemia" "Some HCT patients do not have a cancer di transplant" "May not be a plan for HCT at the time of o "May not be a plan for HCT at the time of o	"In case of urgent treatment it may not alway so it may be able mitigating losses than o "There are multiple acute phases of treatmen "assessment on a continuum" "Needs change in relation to the fact that ther needs to be assessed on treatment then ag "timing of intervention can be different deper "Does not account for transplant in non-mal aplastic anaemia" "Some HCT patients do not have a cancer di "Th is a very good definition, but it does not transplant" "May not be a plan for HCT at the time of c "Add in how it is the job of the whole MDT		atment 6 3 2	ic treatment 6 3 tion 2	ic treatment 6 3 tion 2
may ne g losses ses of tr ses of tr ses of tr atment at fir ant in r ave a c ave a c ut it do ut it do ut it do the t	timent it may no nitigating losses ute phases of tr inuum" ion to the fact t d on treatment a can be differe transplant in r do not have a c do not have a c nition, but it do nition, but it do nor HCT at the t	gent treatment it may no be able mitigating losses altiple acute phases of tr a continuum" e in relation to the fact t e assessed on treatment ervention can be differe ervention can be differe assessed on treatment out for transplant in 1 aemia" out for transplant in 1 aemia" atients do not have a c ood definition, but it do a plan for HCT at the t it is the job of the whol	r BMT" ase of urgent treatment it may no it may be able mitigating losses te are multiple acute phases of th ssment on a continuum" ds change in relation to the fact t eds to be assessed on treatment and of intervention can be differe a change in relation to the fact t in r olastic anaemia" the HCT patients do not have a c a very good definition, but it de ansplant" / not be a plan for HCT at the t in how it is the job of the whol	for BMT" "In case of urgent treatment it may ne so it may be able mitigating losses "There are multiple acute phases of th "assessment on a continuum" "Needs change in relation to the fact th needs to be assessed on treatment "timing of intervention can be differe "There are not account for transplant in 1 aplastic anaemia" "Some HCT patients do not have a c "It is a very good definition, but it de transplant" "May not be a plan for HCT at the the "Add in how it is the job of the whole "contribute"	for BMT" "In case of urgent treatment it may ne so it may be able mitigating losses "There are multiple acute phases of th "assessment on a continuum" "Needs change in relation to the fact the needs to be assessed on treatment "timing of intervention can be differed "timing of intervention can be differed "time a content of the time a content of the time at	for BMT" "In case of urgent treatment it may ne so it may be able mitigating losses "There are multiple acute phases of th "assessment on a continuum" "Needs change in relation to the fact needs to be assessed on treatment "timing of intervention can be differe "Does not account for transplant in 1 aplastic anaemia" "Some HCT patients do not have a c "It is a very good definition, but it de transplant" "May not be a plan for HCT at the t "Add in how it is the job of the whol		atment 6 3 2	ic treatment 6 3 tion 2	ic treatment 6 3 tion 2
	I to inco the it in the it is inco in the pha in the ph	amended to inco gent treatment it be able mitigatir ultiple acute pha n a continuum" e in relation to th e assessed on tre ervention can be ervention can be count for transpl aemia" batients do not h ood definition, h a plan for HCT it is the job of t	r BMT" as of urgent treatment if as of urgent treatment if i it may be able mitigatir i it may be able mitigatir i may be able mitigatir re are multiple acute pha ssment on a continuum" ssment on a continuum" ds change in relation to th eds to be assessed on tre eds to be assessed on tre ng of intervention can be s not account for transpl lastic anaemia" the HCT patients do not h a very good definition, t ansplant" / not be a plan for HCT	 should be amended to inco for BMT" "In case of urgent treatment it so it may be able mitigatir "There are multiple acute pha "assessment on a continuum" "Needs change in relation to the needs to be assessed on trenceds to be assessed on trenceds to be assessed on the needs to be assessed on the "timing of intervention can be "Does not account for transplastic anaemia" "Some HCT patients do not he aplastic anaemia" "May not be a plan for HCT "Add in how it is the job of the contribution." 	 should be amended to incofor BMT" "In case of urgent treatment it so it may be able mitigatir "There are multiple acute pha "assessment on a continuum" "Needs change in relation to the needs to be assessed on tre "Timing of intervention can be "Does not account for transplastic anaemia" "Some HCT patients do not htransplastic anaemia" "May not be a plan for HCT "Mad in how it is the job of the needs is the poly of the needs is	should be amended to inco for BMT" "In case of urgent treatment it so it may be able mitigatir "There are multiple acute pha "assessment on a continuum" "Needs change in relation to th needs to be assessed on tre "timing of intervention can be "Does not account for transpl aplastic anaemia" "Some HCT patients do not h "transplant" "May not be a plan for HCT "Add in how it is the job of t		atment 6 3 2	ic treatment 6 3 tion 2	ic treatment 6 3 tion 2

TABLE 2 Template analysis of proposed definition modifications for haematopoietic cell transplantation (HCT) relevance.

5

BOA The As




FIGURE 1 When in the haematopoietic cell transplantation (HCT) pathway do you think a prehabilitation service could be introduced? In the context of those with a malignancy.

Prehabilitation components

Emotional wellbeing (92.4%, n = 61), nutrition (87.9%, n = 58) and physical activity (81.8%, n = 54)in prehabilitation were considered very important. Additional constituents proposed in free text responses, included social and financial advice, fatigue management, medication optimisation, and the incorporation of family and friends in prehabilitation delivery.

Barriers and facilitators

Just under half of respondents (45.5%, n = 30) felt there were no barriers to prehabilitation delivery in HCT. Where barriers were identified (54.5%, n = 36), the most common were staffing (61.1%, n = 22) and funding (41.7%, n = 15). Table 3 provides themes of barriers and facilitators taken from free text quotes by HCP respondents.

Nutritional care pre-HCT

Nutrition screening

Respondents identified that 50% (n = 12) of the 24 centres nutritionally screened recipients using a validated tool >70% of the time pre-HCT. Barriers to nutritional screening were reported by 61 respondents (92.4%). This included available time (50%, n = 33), training (34.8%, n = 23), staffing (54.5%), n = 36), anthropometric measuring equipment (12.1%, n=8), information communications technology (i.e., ICT) equipment (12.1%, n=8) and clinic space (31.8%, n = 21). Of those HCPs reporting nutrition screening was completed (n = 56) the Malnutrition Universal Screening Tool (MUST) (66.7%, n = 36) was the most widely used. If a patient were identified as at risk of malnutrition during screening, 79.4% (n = 54) of respondents advised they had a dietetic service they could refer to.

centres.
(HCT)
transplantation
haematopoietic cell
UK
, in
prehal
s to p
barrier
on potential
perceptions
Respondent
ABLE 3

Total number of Subtheme respondents ^a $(N = 36)$	Selection of exemplar quotes ^b	Respondent (identifier)
Staffing Provision 18	"Lack of staffing, provision, and resources within therapies to provide a prehabilitation service. My concerns would be time taken away from inpatient work unless it was properly funded"	Dietitian (2)
	"Availability of professionals to complete it"	Haematologist (27)
	"Resources. We try our best but as our dietetic resources are spread across haematology, oncology and HCT we find it very difficult to see patients and implement plans prior to HCTs"	Dietitian (23)
	"Hard for smaller centres to implement with limited staffing. Likely more relevant to allogeneic transplant"	Haematologist (21)
Skill mix 3	"My concern prehabilitation will be delivered by specialist nurses rather than using clinical AHP specialists such as dietitians and physiotherapists"	Haematologist (8)
	"A dedicated AHP team is required in order to delivery this service effectively, to ensure pre and rehabilitation needs are met"	Occupational Therapist (13)
	"For optimum quality and pt benefit, I would prefer it to be provided by haematology dietitians for haematology patients rather than generic "cancer" pre-hab which is often based on solid tumours and often for surgical pathways – very different needs often"	Physiotherapist (35)
Training 3	"Appropriately trained individuals to deliver the same"	Haematologist (16)
	"The service should be delivered by competent staff could be an issue. The staff should be appropriately trained"	Dictitian (28)
Funding 14	"My concern would be a lack of staff and therapy resources to be able to implement a prehabilitation clinic. (Unless the appropriate and additional funding is provided)"	Nurse (1)
	"Funding to support a prehab programme would be the main concern & barrier"	Nurse (11)
	"Current funding is not substantive for dietetics & physio, so could be lost in 2021. It is also in pilot phase, so not embedded into all management pathways. This would require more than current available capacity"	Dietitian (14)
	"Dedicated funding pathways or appropriately trained individuals to deliver the same"	Haematologist (16)
Delivery 4	"Timing of initiative, patients are referred from multiple centres so difficult to find a good time to offer them Physiotherapist (5) prehab as they are going through other aggressive treatments"	Physiotherapist (5)
	"Information overload!"	Haematologist (17)
	"Concerns as some patients travel a distance and would not be able to easily attend a local program"	Dietitian (18)

IHND

Nutrition assessment

- IHND

If the screening tool assessed someone as at risk, 61%(n = 41) of respondents reported that patients would have a nutritional assessment by a trained professional >70% of the time. Most nutritional assessments within centres were conducted using the dietetic care $process^{29}$ (34.1%, n = 14). Less frequently reported processes were patient generated subjective global assessment (2.4%, n = 1) and handgrip strength (4.8%, n = 2), a measure of function. MUST (12.2%, n = 5) was reported as an assessment technique in the "other" response options by some respondents. Dietitians most commonly (91.6%, n = 22) conducted assessments within centres. Handgrip strength, a measure of physical function was reported to be used as part of nutritional assessments by 32.2% (n = 19) of 59 respondents.

Biochemical monitoring

Respondents (87.9%, n = 58) reported liver (86.2%, n = 50) and kidney function (86.2%, n = 50) alongside blood pressure (79.3%, n = 46) were routinely checked >70% of the time pre-HCT. Blood glucose (46.5%, n = 27) and lipid (32.8%, n = 19) levels were not routinely collected. Where samples were collected, only 12.1% (n = 8) were reported to be fasted; however, 45.5% (n = 30) felt that fasted samples could be facilitated. Details of HCP perceived frequency of biochemical and nutritional systemic measures taken pre-HCT are provided in the Supporting information (Figure S1).

Body composition assessment

Body composition pre-HCT was reported to be measured >70% of the time by 45.8% (n = 27) of respondents (n = 59). Methods of body composition were reported by 43 (65.1%) respondents. Body mass index (BMI) (70.2%, n = 33) was the most common. More comprehensive methods such as triceps skin fold (4.3%, n = 2), mid upper arm circumference (6.4%, n = 3), waist circumference (2.1%, n = 1) and bioelectrical impedance analysis (2.1%, n = 1) were rarely used and 12.8% (n = 6) did not know. Haematology specialist dietitians were most likely to be reported to conduct body composition measurements (39.7%, n = 23 of 58). Of 61 respondents, BMI was felt to be most feasible in practice (82%, n = 50). However, 86.9% (n = 53) of HCPs felt centres had the equipment to conduct an alternative body composition measure to BMI.

Dietary advice provision

More non-dietitians (64.1%, n = 25) reported that all patients would receive routine (>70% of time) dietary advice

pre-HCT than dietitians (40.7%, n = 11). This differed, however, when those who had been identified as at nutritional risk (clinically or via a screening tool) were considered with both non-dietitians (69.2%, n = 27) and dietitians (74.1%, n = 20) reporting similar likelihood of routine (>70% of time) dietary advice pre-HCT.

Forty-five respondents (68.2%) reported they provided dietary advice pre-HCT, accounting for 70% (n = 28) of non-dietitians and 65.3% (n = 17) of dietitians. When asked how often they "individualised" this dietary advice based on clinical circumstances or preferences over delivery of generic advice, 44 HCPs responded. Of the 44 respondents, all dietitians (100%, n = 17) reported the personalisation of dietary advice >70% of the time compared to nondietitians (59.3%, n = 16). Information used for personalisation of dietary advice is available in the Supporting information (Table S1).

Of the 45 HCPs who reported they provided dietary advice, 71.1% (n = 32) reported giving dietary advice on total energy intake, 46.7% (n = 21) on protein, 44.4% (n = 20) on fat and 24.4% (n = 11) on fibre. Where respondents provided advice, there were variations by profession (Figure 2) but the most common patterns of dietary advice pre-HCT were high-protein, high-energy, high-fat and moderate fibre. The type of advice given by dietitians and non-dietitians is provided in the Supporting information (Figure S2a-d).

Sixty-one HCPs reported types of specialist dietary advice they gave, with just over half providing neutropenic dietary advice pre-HCT (54.3%, n = 19, non-dietitians vs. 61.5%, n = 16, dietitians). Provision of probiotic (14.3%, n = 5 non-dietitians vs. 34.6%, n = 9 dietitians) and prebiotic advice (2.9%, n = 1 non-dietitian; 15.4%, n = 4 dietitians) was less frequent and varied between dietitians and nondietitians (see Supporting information, Table S2). Half of the respondents did not discuss micronutrients pre-HCT; where they were discussed, vitamin D was the most frequently advised on (17.1%, n = 6 non-dietitians vs. 38.5%, n = 10 dietitians). However, advice on vitamin and mineral supplementation was given more frequently by dietitians than non-dietitians (see Supporting information, Table S3).

Enteral feeding provision

Of sixty-one HCPs, just over one-third (35.9%, n = 14, non-dietitians vs. 44.4%, n = 12, dietitians) reported the prophylactic placement of enteral feeding tubes pre-HCT. Where used, nasogastric (39.3%, n = 24) or nasojejunal (21.3%, n = 13) feeding tubes were the most frequently reported (see Supporting information, Table S4). The most common reported indications for prophylactic tube placement were BMI ≤ 17.5 kg/m² (26.2%, n = 16), 10% weight loss in 6 months (21.3%,




FIGURE 2 Types of dietary advice given by healthcare professionals (HCPs) pre-haematopoietic cell transplantation (HCT) (N = 45).

n = 13) and BMI 17.5–19.5 kg/m² (19.7%, n = 12) (see Supporting information, Table S5).

Exercise advice provision

Of fifty-nine HCPs, less than half (n = 25, 42.4%) reported patients would receive physical activity advice as part of routine practice (>70% of time) pre-HCT. More specifically, 13.6% (n = 8) reported exercise advice pre-HCT was given all the time, 28.8% (n = 17) often, 25.4% (n = 15) sometimes, 16.9% (n = 10) rarely and 15.2% (n = 9) never. Most HCPs (76.9%, n = 30) reported that activity levels were rarely or never measured pre-HCT by questionnaire or physical assessment.

DISCUSSION

This is the first UK survey to investigate HCP reported provision of prehabilitation and nutritional care pre-HCT. The findings highlight limited access to prehabilitation within centres, no standardisation of the constituents delivered and variable nutrition provision. Yet the value of both prehabilitation and nutrition was well recognised by HCPs.

Defining prehabilitation in HCT

HCP perceptions on definitions for prehabilitation in the context of HCT have not previously been considered. Because $92.3\%^1$ of European HCT recipients will have a cancer diagnoses, the cancer prehabilitation definition by Silver and Baima²² was reviewed by HCPs for relevance to HCT. Half the respondents reporting this definition could be directly translatable to HCT despite referring to cancer. A further one-third felt it needed refinement to reflect the multiphasic treatment cycles pre-HCT, potential acute presentation, non-malignant presentations, short lead in times and constituents considered important to future programmes.

In the proposed Miller et al., definition, physical wellbeing refers to nutritional adequacy, functional fitness, and appropriate management of side-effects to support activities of daily living. This may require a range of supportive interventions, for example nutritional care, ^{17,30} physical activity,³¹ social support³² (finance, carer support) and medical optimisation. In this definition, psychological wellbeing refers to a person's ability to be aware, manage and express their emotions in a way that improves life satisfaction, meaning and purpose and minimise the impact on their health outcomes. Strategies to support emotional

IHND

well-being may include self-help programmes, resources or talking therapies (cognitive behavioural therapy³³ or acceptance and commitment therapy³⁴) facilitated by an appropriately qualified person.

Prehabilitation constituents, such as nutrition, emotional wellbeing, and physical activity were considered important by HCPs, as per other guidelines.^{17,26} Additional, aspects such as multidisciplinary delivery, social and financial support, fatigue management and carer support were identified as important considerations for HCT. However, each prehabilitation programme will need to be personalised based on the person's diagnosis, circumstances, type of transplantation and any prior deconditioning leading up to HCT. Although the proposed definition by Miller et al. is informed by HCP perceptions of prehabilitation programme requirements, further refinement with those with lived experience is recommended.

Delivering prehabilitation

Our capacity to understand optimal intervention, constituents, duration, intensity and timing of prehabilitation programmes is limited by low-quality heterogenous prehabilitation studies^{25,35} and limited evidence in HCT. Elective surgical prehabilitation programmes are mainly delivered in the context of *de novo* treatment, which is not reflective of HCT pathways. More than 80% of HCT recipients receive up to three cycles of chemotherapy³⁶ with 2–4 weeks of cellular recovery pre-HCT. As such, HCT may have greater similarities to, and learning from, prehabilitation in neo-adjuvant chemotherapy (three to six cycles) with its slightly longer 3–6 weeks of preoperative cellular recovery^{37,38} but evidence with respect to this is also lacking.^{26,39}

More than 80% of respondents felt prehabilitation was deliverable between the end of consolidation treatment and admission for HCT (approximately 2–4 weeks), with 60.6% feeling earlier initiation at the end of first cycle of chemotherapy or at decision for HCT was possible. This reflects cyclical (multiphasic) provision through chemotherapy/treatment prior to HCT, comprised of both prehabilitation and rehabilitation^{40,41} (Figure 3). Currently published protocols for prehabilitation trials in HCT report intervention windows as either pre-HCT only^{42–46} or on a continuum (pre, peri and post),⁴⁶ with only one including personalised nutrition.⁴³

Nutritional care pre-HCT

The impact of obesity, malnutrition, and secondary sarcopenia on HCT outcomes^{3,8,12,47} is well recognised. However, the implementation of nutritional practices that support the identification and management of these risks was variable. Malnutrition screening is a systematic approach used to identify those at nutritional risk, quickly and cost efficiently at scale. Although consensus is lacking on the optimal approach,¹⁷ early screening for malnutrition is recommended^{17,48,49} preferentially with a validated measure⁵⁰; however, only 50% of UK centres screened pre-HCT using a validated tool (e.g., MUST).




FIGURE 3 Example pathway for people with haematological cancer reflecting the potential impacts of multicycle chemotherapy prior to haematopoietic cell transplantation (HCT) and prehabilitation/rehabilitation considerations at each stage.

This compares to 57% of European Bone Marrow Transplant (EBMT) centres, with only 16% using a validated tool.¹⁶

For those identified as at risk of malnutrition during screening a more comprehensive assessment (e.g., Dietetic Care Process or Subjective Global Assessment) is then recommended.¹⁷ The Global Leader's Initiative in Malnutrition (i.e., GLIM) published an evidence-based framework for the diagnosis and grading of malnutrition in adults⁵⁰ and this includes approaches for assessment. Five core diagnostic criteria were identified: three etiological (nonvolitional weight loss, low body mass index (BMI), reduced muscle mass) and two phenotypic (reduced food intake or assimilation and disease burden/inflammation).⁵⁰

Weight and height were the most routinely reported measures to be collected prior to HCT. Non-volitional (unintentional) weight loss of more than 10% prior to HCT may be associated with poor treatment outcomes,⁵¹ with impact varying dependant on diagnosis and type of transplantation.⁵²

Body composition also impacts HCT outcomes⁵³ but there is a lack of standardised methodology between studies⁵⁴ on optimal approaches to measurements. Within this study, BMI was reported as the most feasible measure of body composition to be collected prior to HCT by HCPs. However, used alone, this significantly underestimates incidence of malnutrition compared to validated tools, particularly in people with obesity.⁵⁵ Alongside this, BMI does not differentiate between fat and fat free mass, where people of any weight and age can be sarcopenic (low muscle mass).³⁰ UK HCPs rarely used comprehensive measures (e.g., computed tomography, dual energy X-ray absorptiometry or bioelectrical impedance analysis) of body composition, limiting the potential to identify low muscle mass in practice. These approaches also allow monitoring of changes in fat mass. which have been shown to increase during HCT.⁵⁶ The clinical implications of these changes are less well described, but bone marrow adipocyte accumulation in both obesity and ageing has been linked to impaired haemopoiesis.⁵⁷

Nutrition guidelines recommend the inclusion of strategies to diagnose and monitor for low muscle mass as part of nutritional/dietetic assessments.^{17,50} The most appropriate method will depend on resources, staff and training available, alongside the target population.⁵⁸ As more research is published, there is also emerging data on population specific reference ranges and adjustment factors to ensure correct interpretation.^{58–60}

Sarcopenic screening may help identify those at risk of low muscle mass, quickly at scale to support early intervention, in time and resource limited settings. Although there is a range of available screening approaches for sarcopenia,⁶¹ most were JHND

11

designed in the context of frailty and ageing⁶² (primary sarcopenia) and not cancer (secondary sarcopenia¹¹). These screening measures often incorporate measure(s) of function, rather than a discrete measure of low muscle mass. An example is the Strength, assistance with walking, rising from a chair, climbing stairs, and falls (SARC-F) six-item questionnaire⁶³ or its derivatives (e.g., SARC-F-calf⁶⁴ [SARC-F plus calf circumference] and the paediatric SARC-F [PED-SARC-F]⁶⁵). SARC-F-calf has shown good predictive potential⁶⁴ for low muscle mass in other cancer cohorts; however, further studies in HCT and within discrete populations (<60 years, ethnicity and BMI) are needed. Handgrip strength, can be used as a simple indirect or predictive measure of sarcopenia⁶⁶ and malnutrition risk,⁶⁷ but small samples and heterogeneity in procedural reporting limits comparisons between studies.⁶⁸ Calf circumference could also offer an alternative indicator of low muscle mass^{69,70} and malnutrition.⁷¹ Procedural recommendations include direct skin measures, and so there may be practical limitations as to where and how calf circumference may be collected in a clinic setting.

Less than half of the HCPs in centres reported routine provision of exercise advice and even less reported routine assessment of physical activity pre-HCT. However, the target audience for this survey were nurses, medics and dietitians because of its nutritional focus, and so this may reflect a lack of awareness or physiotherapist representation in the survey, such that further investigation is warranted.

Provision of dietary advice was interdisciplinary, and the level of personalisation delivered was determined by the profession delivering the advice. HCPs reported that dietary advice pre-HCT focused on total energy needs and high-fat dietary advice, with only one-third advising on protein and even less on fibre. This type of advice has potential limitations; for example, the optimisation of muscle mass and function requires protein, energy and nutrient advice.⁷² The provision of specialist dietary advice such as pre- and probiotics, micronutrients and neutropenic diet was rare outside dietitians; this could be a result of recognised gaps in nutrition education and training of non-dietetic HCPs.^{73,74} Vitamin D was the most frequently discussed vitamin pre-HCT, potentially reflecting its emergent role in anaemia,⁷⁵ infection and GvHD.^{75,76} thus warranting further HCP training. Neutropenic dietary advice was routinely provided; however, the level of restriction advised was not evaluated in this study. While, neutropenic restriction is still practiced there is insufficient evidence to support very restrictive practices⁷⁷ the British Dietetic Association has recommended relaxation of restrictions as a result of gaps in the evidence base.⁷⁸ Prophylactic tube feeding was rare with unintentional weight loss and BMI as the primary indicators for feeding, which is in line with national and international recommendations.^{19,79}

IHND

This survey was comprehensive and allowed greater understanding of interprofessional and between centre variation than similar studies. However, it was not possible to obtain representation from all centres or all target professionals within a site. There were notable discrepancies in reported provision of nutritional care between professionals within a site, raising important considerations for other surveys of multiprofessional intervention delivery. Increased knowledge of nutrition provision within centres and between HCPs could be improved via inclusion of allied services in multidisciplinary teams, documented processes and nutrition training. This study also focused on HCP perceptions of prehabilitation for HCT as a whole and did not explore HCP perceptions on differential service needs by type of transplant or diagnosis.

CONCLUSIONS

Nutrition and prehabilitation in HCT are perceived as important and deliverable by HCPs, but current provision in UK centres is limited and inconsistent. Although limited, HCT prehabilitation research does exist, future studies should include detailed intervention descriptions in discrete haematological populations, including core outcome frameworks. Furthermore, although international HCT¹⁸ standards recommend access to allied services, such as dietitians, they lack detail on minimum standards of pre, peri- and post-HCT nutrition, relative to the size, throughput and age range of the unit. Defining minimum nutrition standards in HCT via national organisations (e.g., BSBMTCT) or refined accreditation standards (Joint Accreditation Committee ISCT-Europe & EBMT)¹⁸ may help address these unmet needs, reducing inequalities in access identified in this study, guiding centres and commissioners. Further research is warranted to quantify the impact of nutrition and prehabilitation interventions on survival outcomes, patient experience and health economics associated with HCT.

TRIALS REGISTRATION

CTCS 19-01 (BSBMTCT CTSC). Clinicaltrials.gov: NCT05352789.

AUTHOR CONTRIBUTIONS

Laura J. Miller contributed to the concept, design, delivery, analysis and article drafting. Diana M. Greenfield contributed to design, qualitative analysis, critical review and revision of article. Vanessa Halliday contributed to design, critical review and revision of article. Guruprasad P. Aithal contributed to the design, critical review and revision of the article. John A. Snowden contributed to the design, critical review and revision of the article. JL contributed to distribution of survey, coordination of some responses from centres and article review.

ACKNOWLEDGEMENTS

We thank BSBMTCT Clinical Trials Sub Committee for facilitating survey dissemination and initial advice on site engagement; Dr Jennifer Byrne, Nottingham University Hospitals NHS Trust, for identifying BSBMTCT as a collaborator; Dr Rachel Pearce, BSBMTCT statistician, for initial advice on statistical approaches; Kathryn Blount, Nottingham University Hospitals NHS Trust, for proof-reading the manuscript; Dr Sarah Crozier, Consultant Psychologist, Nottingham University Hospitals NHS Trust and Dr Orla McCourt, Physiotherapist, University College London Hospitals for their peer discussion. There was no allocated funding for this research.

CONFLICTS OF INTEREST STATEMENT

The authors declare that there are no conflicts of interest.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ETHICAL STATEMENT

The study was registered with the Health Research Authority who confirmed that ethics approval was not required. All local governance and GDPR processes were followed.

ORCID

Laura J. Miller D http://orcid.org/0000-0003-3056-5443

PEER REVIEW

The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/jhn.13315.

REFERENCES

- Passweg JR, Baldomero H, Chabannon C, Basak GW, de la Cámara R, Corbacioglu S, et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant. 2021;56:1651–64.
- Espinoza M, Perelli J, Olmos R, Bertin P, Jara V, Ramírez P. Nutritional assessment as predictor of complications after hematopoietic stem cell transplantation. Rev Bras Hematol Hemoter. 2016;38:7–14.
- 3. Fuji S, Einsele H, Savani BN, Kapp M. Systematic nutritional support in allogeneic hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2015;21:1707–13.
- 4. Steinberg A, Asher A, Bailey C, Fu JB. The role of physical rehabilitation in stem cell transplantation patients. Supp Care Cancer. 2015;23:2447–60.

- Ehrlich KB, Miller GE, Scheide T, Baveja S, Weiland R, Galvin J, et al. Pre-transplant emotional support is associated with longer survival after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2016;51:1594–8.
- 6. Inamoto Y, Lee SJ. Late effects of blood and marrow transplantation. Haematologica. 2017;102:614–25.
- Pereira AZ, Victor ES, Vidal Campregher P, Piovacari SM, Bernardo Barban JS, Pedreira WL Jr, et al. High body mass index among patients undergoing hematopoietic stem cell transplantation: results of a cross-sectional evaluation of nutritional status in a private hospital. Nutr Hosp. 2015;32:2874–9.
- Pereira AZ, de Almeida-Pitito B, Eugenio GC, Ruscitto do Prado R, Silva CC, Hamerschlak N. Impact of obesity and visceral fat on mortality in hematopoietic stem cell transplantation. J Parenter Enteral Nutr. 2021;45:1597–603.
- Meloni G, Proia A, Capria S, Romano A, Trapé G, Trisolini S, et al. Obesity and autologous stem cell transplantation in acute myeloid leukemia. Bone Marrow Transplant. 2001;28:365–7.
- Lazarow H, Nicolo M, Compher C, Kucharczuk CR, Stadtmauer EA, Landsburg DJ. Nutrition-related outcomes for autologous stem cell transplantation patients. Clin Lymphoma Myeloma Leuk. 2019;19:e393–8.
- Anjanappa M, Corden M, Green A, Roberts D, Hoskin P, McWilliam A, et al. Sarcopenia in cancer: risking more than muscle loss. Tech Innov Patient Support Radiat Oncol. 2020;16: 50–7.
- Armenian SH, Xiao M, Berano Teh J, Lee B, Chang HA, Mascarenhas K, et al. Impact of sarcopenia on adverse outcomes after allogeneic hematopoietic cell transplantation. JNCI: J Natl Cancer Inst. 2019;111:837–44.
- Majhail NS, Flowers ME, Ness KK, Jagasia M, Carpenter PA, Arora M, et al. High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2009;43:49–54.
- Greenfield DM, Salooja N, Peczynski C, van der Werf S, Schoemans H, Hill K, et al. Metabolic syndrome and cardiovascular disease after haematopoietic cell transplantation (HCT) in adults: an EBMT cross-sectional non-interventional study. Bone Marrow Transplant. 2021;56:2820–5.
- DeFilipp Z, Duarte RF, Snowden JA, Majhail NS, Greenfield DM, Miranda JL, et al. Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT. Bone Marrow Transplant. 2017;52:173–82.
- 16. Peric Z, Botti S, Stringer J, Krawczyk J, van der Werf S, van Biezen A, et al. Variability of nutritional practices in peritransplant period after allogeneic hematopoietic stem cell transplantation: a survey by the Complications and Quality of Life Working Party of the EBMT. Bone Marrow Transplant. 2018;53: 1030–7.
- Arends J, Baracos V, Bertz H, Bozzetti F, Calder PC, Deutz NEP, et al. ESPEN expert group recommendations for action against cancer-related malnutrition. Clin Nutr. 2017;36:1187–96.
- The Joint Accreditation Committee ISCT-Europe & EBMT (JACIE). FACT-JACIE hematopoietic cellular therapy accreditation manual, eighth edition, Ver 8.2: Standard B3.11.1.1. 2021 [cited 2023 Sept]. Available from: https://www.ebmt.org/sites/ default/files/2021-12/STS_5_2_042_FACT-JACIE% 20AccreditationMANUAL%20Eighth%20Edition_8_2_R3_ 12142021_ForWeb.pdf (accessed September 2023)
- National Health Service. Next Steps on Five Year Forward View.
 2019 [cited 2023 Sept]. Available from: https://www.england.nhs. uk/publication/next-steps-on-the-nhs-five-year-forward-view
- National Health Service. Achieving World Class Cancer Outcomes: progress report 2016-2020. 2018 [cited 2023 Sept]. Available from: https://www.england.nhs.uk/publication/ achieving-world-class-cancer-outcomes/

- National Health Service. NHS Long term plan. 2019 [cited 2023 Sept]. Available from: https://www.longtermplan.nhs.uk/
- 22. Silver JK, Baima J. Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehab. 2013;92:715–27.
- Santa Mina D, Scheede-Bergdahl C, Gillis C, Carli F. Optimization of surgical outcomes with prehabilitation. Appl Physiol Nutr Metabol. 2015;40:966–9.
- O'Connor D, Loke J, Brown M, Stanworth SJ, Young A, Prue G. Non-pharmacological supportive-care interventions in acute myeloid leukaemia: a review of randomised controlled trials. Br J Haematol. 2021;195:e97–e113.
- Gillis C, Davies SJ, Carli F, Wischmeyer PE, Wootton SA, Jackson AA, et al. Current landscape of nutrition within prehabilitation oncology research: a scoping review. Front Nutr. 2021;8:644723.
- Macmillan Cancer Support. Principles and guidance for prehabilitation within the management and support of people with cancer. 2020 [cited 2023 Sept]. Available from: https://www. macmillan.org.uk/assets/prehabilitationguidance-for-people-withcancer.pdf
- Artino AR, La Rochelle JS, Dezee KJ, Gehlbach H. Developing questionnaires for educational research: AMEE Guide No. 87. Med Teach. 2014;36:463–74.
- Brooks J, McCluskey S, Turley E, King N. The utility of template analysis in qualitative psychology research. Qual Res Psychol. 2015;12:202–22.
- British Dietetic Association. Model and Process for Nutrition and Dietetic Practice. 2016 [cited 2023 Sept]. Available from: https:// www.bda.uk.com/static/376a7558-80cb-46f8-bd8712d9725f590a/ 2021-BDA-Model-and-Process-for-Nutrition-and-Dietetic-Practice.pdf
- Prado CM, Cushen SJ, Orsso CE, Ryan AM. Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact. Proc Nutr Soc. 2016;75:188–98.
- Steinberg A, Asher A, Bailey C, Fu JB. The role of physical rehabilitation in stem cell transplantation patients. Supp Care Cancer. 2015;23(8):2447–60.
- Nørskov KH, Yi JC, Crouch M-L, Fiscalini AS, Flowers MED, Syrjala KL. Social support as a moderator of healthcare adherence and distress in long-term hematopoietic cell transplantation survivors. J Cancer Surviv. 2021;15(6):866–75.
- Kilkus JL. Applications of cognitive behavioral therapy in cancer survivorship. Psychotherapy. 2022;59(2):245–60.
- Mathew A, Doorenbos AZ, Jang MK, Hershberger PE. Acceptance and commitment therapy in adult cancer survivors: a systematic review and conceptual model. J Cancer Surviv. 2021;15:427–51.
- McIsaac DI, Gill M, Boland L, Hutton B, Branje K, Shaw J, et al. Prehabilitation in adult patients undergoing surgery: an umbrella review of systematic reviews. Br J Anaesth. 2022;128:244–57.
- 36. Snowden JA, Sánchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours, and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant. 2022;57:1217–39.
- Zylstra J, Whyte GP, Beckmann K, Pate J, Santaolalla A, Gervais -Andre L, et al. Exercise prehabilitation during neoadjuvant chemotherapy may enhance tumour regression in oesophageal cancer: results from a prospective non-randomised trial. Br J Sports Med. 2022;56(7):402–9.
- Miralpeix E, Sole-Sedeno JM, Rodriguez-Cosmen C, Taus A, Muns MD, Fabregó B, et al. Impact of prehabilitation during neoadjuvant chemotherapy and interval cytoreductive surgery on ovarian cancer patients: a pilot study. World J Surg Oncol. 2022;20:46.

13

BOA The Asso

 Falz R, Bischoff C, Thieme R, Lässing J, Mehdorn M, Stelzner S, et al. Effects and duration of exercise-based prehabilitation in surgical therapy of colon and rectal cancer: a systematic review and metaanalysis. J Cancer Res Clin Oncol. 2022;148(9):2187–213.

RDA The Ass

14

IHND

- 40. Mills T, Marks E, Reynolds T, et al (2017). Rehabilitation: essential along the continuum of care. In: Jamison DT, Gelband H, Horton S, et al. Disease control priorities: improving health and reducing poverty. 3rd ed, Chapter 15. Washington (DC): The International Bank for Reconstruction and Development/The World Bank.
- 41. Santa Mina D, van Rooijen SJ, Minnella EM, Alibhai SMH, Brahmbhatt P, Dalton SO, et al. Multiphasic prehabilitation across the cancer continuum: a narrative review and conceptual framework. Front Oncol. 2021;10:598425.
- 42. Potiaumpai M, Schmitz KH, Mineishi S, Naik S, Wirk B, Rakszawski K, et al. IMPROVE-BMT: a protocol for a pilot randomised controlled trial of prehabilitation exercise for adult haematopoietic stem cell transplant recipients. BMJ Open. 2023;13:e066841.
- Dennett AM, Porter J, Ting SB, Taylor NF. Prehabilitation to improve outcomes afteR Autologous sTem cEll transplantation (PIRATE): a pilot randomised controlled trial protocol. PLoS One. 2023;18:e0277760.
- 44. Mawson S, Keen C, Skilbeck J, Ross H, Smith L, Dixey J, et al. Feasibility and benefits of a structured prehabilitation programme prior to autologous stem cell transplantation (ASCT) in patients with myeloma; a prospective feasibility study. Physiotherapy. 2021;113:88–99.
- 45. Wood WA, Weaver M, Smith-Ryan AE, Hanson ED, Shea TC, Battaglini CL. Lessons learned from a pilot randomized clinical trial of home-based exercise prescription before allogeneic hematopoietic cell transplantation. Supp Care Cancer. 2020;28: 5291–8.
- 46. McCourt O, Fisher A, Ramdharry G, Land J, Roberts AL, Rabin N, et al. Exercise prehabilitation for people with myeloma undergoing autologous stem cell transplantation: results from PERCEPT pilot randomised controlled trial. Acta Oncol. 2023;62:696–705.
- Barazzoni R, Gortan Cappellari G. Double burden of malnutrition in persons with obesity. Rev EndocrMetab Disord. 2020;21:307–13.
- Reber E, Schönenberger KA, Vasiloglou MF, Stanga Z. Nutritional risk screening in cancer patients: the first step toward better clinical outcome. Front Nutr. 2021;8:603936.
- Muscaritoli M, Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, et al. ESPEN practical guideline: clinical nutrition in cancer. Clin Nutr. 2021;40:2898–913.
- Jensen GL, Cederholm T, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi T, et al. GLIM criteria for the diagnosis of malnutrition: a consensus report from the global clinical nutrition community. JPEN J Parenter Enteral Nutr. 2019;43:32–40.
- Tamaki M, Nakasone H, Nakamura Y, Kawamura M, Kawamura S, Takeshita J, et al. Body weight loss before allogeneic hematopoietic stem cell transplantation predicts survival outcomes in acute leukemia patients. Transplant Cell Ther. 2021;27:340.e1–340.e6.
- Eglseer D, Bauer S, Huber-Kra
 ßnitzer B, Greinix H. Malnutrition risk prior to hematopoietic stem cell transplantation predicts mortality in adults. Bone Marrow Transplant. 2021;56:2268–71.
- Kyle UG, Chalandon Y, Miralbell R, Karsegard VL, Hans D, Trombetti A, et al. Longitudinal follow-up of body composition in hematopoietic stem cell transplant patients. Bone Marrow Transplant. 2005;35:1171–7.
- Price S, Kim Y. Body composition impacts hematopoietic stem cell transplant outcomes in both autologous and allogeneic transplants: a systematic review. Nutr Cancer. 2022;74:2731–47.

- 55. van Vliet IMY, Gomes-Neto AW, de Jong MFC, Bakker SJL, Jager-Wittenaar H, Navis GJ. Malnutrition screening on hospital admission: impact of overweight and obesity on comparative performance of MUST and PG-SGA SF. Eur J Clin Nutr. 2021;75:1398–406.
- 56. DeFilipp Z, Troschel FM, Qualls DA, Li S, Kuklinski MW, Kempner ME, et al. Evolution of body composition following autologous and allogeneic hematopoietic cell transplantation: incidence of sarcopenia and association with clinical outcomes. Biol Blood Marrow Transplant. 2018;24:1741–7.
- 57. Ambrosi TH, Scialdone A, Graja A, Gohlke S, Jank AM, Bocian C, et al. Adipocyte accumulation in the bone marrow during obesity and aging impairs stem cell-based hematopoietic and bone regeneration. Cell Stem Cell. 2017;20:771–84.e6.
- Barazzoni R, Jensen GL, Correia MITD, Gonzalez MC, Higashiguchi T, Shi HP, et al. Guidance for assessment of the muscle mass phenotypic criterion for the Global Leadership Initiative on Malnutrition (GLIM) diagnosis of malnutrition. Clin Nutr. 2022;41:1425–33.
- Gonzalez MC, Mehrnezhad A, Razaviarab N, Barbosa-Silva TG, Heymsfield SB. Calf circumference: cutoff values from the NHANES 1999-2006. Am J Clin Nutr. 2021;113:1679–87.
- Blue MNM, Tinsley GM, Ryan ED, Smith-Ryan AE. Validity of body-composition methods across racial and ethnic populations. Adv Nutr. 2021;12:1854–62.
- Ackermans, LLGC, Rabou J, Basrai M, Schweinlin A, Bischoff SC, et al. Screening, diagnosis and monitoring of sarcopenia: When to use which tool? Clin Nutr ESPEN. 2022;48: 36–44.
- 62. Lu J, Xu Q, Zhu S, Chen L, Ding L, Hua H, et al. Comparison of five sarcopenia screening tools in preoperative patients with gastric cancer using the diagnostic criteria of the European Working Group on Sarcopenia in Older People 2. Nutrition. 2022;95:111553.
- Malmstrom TK, Miller DK, Simonsick EM, Ferrucci L, Morley JE. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 2016;7:28–36.
- Fu X, Tian Z, Thapa S, Sun H, Wen S, Xiong H, et al. Comparing SARC-F with SARC-CalF for screening sarcopenia in advanced cancer patients. Clin Nutr. 2020;39:3337–45.
- 65. Verwaaijen EJ, van der Torre P, Vormoor J, Pieters R, Fiocco M, Hartman A, et al. Novel adaption of the SARC-F score to classify pediatric hemato-oncology patients with functional sarcopenia. Cancers. 2023;15:320.
- 66. Blanquet M, Ducher G, Sauvage A, Dadet S, Guiyedi V, Farigon N, et al. Handgrip strength as a valid practical tool to screen early-onset sarcopenia in acute care wards: a first evaluation. Eur J Clin Nutr. 2021;76:56–64.
- Mendes NP, Barros TA, Faria BS, Aguiar ES, Oliveira CA, Souza ECG, et al. Handgrip strength as predictor of undernutrition in hospitalized patients with cancer and a proposal of cut-off. Clin Nutr ESPEN. 2020;39:210–4.
- Sousa-Santos AR, Amaral TF. Differences in handgrip strength protocols to identify sarcopenia and frailty—a systematic review. BMC Geriatr. 2017;17:238–59.
- Trussardi Fayh AP, de Sousa IM. Comparison of revised EWGSOP2 criteria of sarcopenia in patients with cancer using different parameters of muscle mass. PLoS One. 2021;16:e0257446.
- Sousa IM, Bielemann RM, Gonzalez MC, da Rocha IMG, Barbalho ER, de Carvalho ALM, et al. Low calf circumference is an independent predictor of mortality in cancer patients: A prospective cohort study. Nutrition. 2020;79-80:110816.
- Ferretti RL, Maia-Lemos PS, Guedes KJT, Luisi FAV, Caran EMM. Cutoff values for calf circumference to predict malnutrition in children and adolescents with malignant

74.

79

2023.48.75-86

2020;11:366-80.

2015;22:432-8.

treat low muscle mass in cancer. J Cachexia Sarcopenia Muscle. 73. Murphy JL, Munir F, Davey F, Miller L, Cutress R, White R, et al. The provision of nutritional advice and care for cancer patients: a UK national survey of healthcare professionals. Supp Care Cancer. 2021;29:2435-42. Macaninch E, Buckner L, Amin P, Broadley I, Crocombe D, Herath D, et al. Time for nutrition in medical education. BMJ Nutr Prev Health. 2020;3:40-8. 75. Smith EM, Tangpricha V. Vitamin D and anemia: insights into an emerging association. Curr Opin Endocrinol Diabetes Obes. 76. Hong S, Ferraro CS, Hamilton BK, Majhail NS. To D or not to D: vitamin D in hematopoietic cell transplantation. Bone Marrow Transplant. 2020;55:2060-70. 77. Sonbol MB, Jain T, Firwana B, Hilal T, Deleon T, Murad A, et al. Neutropenic diets to prevent cancer infections: updated systematic review and meta-analysis. BMJ Suppor Palliat Care. 2019;9(4):425-33. https://doi.org/10.1136/bmjspcare-2018-001742. 78. British Dietetic Association. BDA policy statement: safer eating with neutropenia. 2020 [cited 2023 Sept]. Available from: https:// www.bda.uk.com/resource/neutropenic-dietary-advice-for-National Institute for Health and Clinical Excellence. Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition: clinical guideline [CG32]. 2017 [cited 2023 Sept]. Available from: https://www.nice.org.uk/guidance/

AUTHOR BIOGRAPHIES

cg32/chapter/Recommendations

haematology-patients.html

Laura J. Miller is a Haematology research dietitian and NIHR PhD candidate, Nottingham University Hospitals (NUH) NHS Trust and the School of Medicine, University of Nottingham, with extensive clinical experience in haematological conditions.

neoplasms: a new parameter for assessment? Clin Nutr Open Sci.

72. Prado CM, Purcell SA, Laviano A. Nutrition interventions to

Vanessa Halliday is a Registered dietitian and faculty Director of Education for Health, School of Medicine and Population Health, University of Sheffield, UK.

John A. Snowden is a Consultant haematologist and Direct of Blood and Marrow Transplant (BMT), Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.

Guruprasad P. Aithal is a professor of hepatology and honorary consultant gastroenterologist; NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals and the University of Nottingham, Nottingham, UK.

Julia Lee is head of the British Bone Marrow Transplant and Cellular Therapy (BSBMTCT) Data Registry and senior information risk owner for BSBMTCT, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Diana M. Greenfield is a consultant nurse in late effects, Sheffield Teaching Hospitals NHS Foundation Trust and Honorary Professor, Cancer Survivorship, Department of Clinical Oncology and Metabolism, University of Sheffield, UK.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Miller LJ, Halliday V, Snowden JA, Aithal GP, Lee J, Greenfield DM. Health professional attitudes and perceptions of prehabilitation and nutrition before haematopoietic cell transplantation. J Hum Nutr Diet. 2024;1-15. https://doi.org/10.1111/jhn.13315